Brief: FDA Grants Fast Track Designation To Nuvectis Pharma's Nxp800 For The Treatment Of Platinum-Resistant, Arid1a-Mutated Ovarian Carcinoma
01/12/2022 13:03
Dec 1 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* FDA GRANTS FAST TRACK DESIGNATION TO NUVECTIS PHARMA'S
NXP800
FOR THE TREATMENT OF PLATINUM-RESISTANT, ARID1A-MUTATED OVARIAN
CARCINOMA
Source text for Eikon: ID:nGNX49dB6c
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin